Kava T, Lindqvist A, Karjalainen J, Laitinen L A
Respiration. 1987;51(2):98-104. doi: 10.1159/000195173.
Polyvalent killed influenza virus vaccine or saline was administered subcutaneously to 27 asthmatics to investigate the effect of influenza vaccine on respiratory function and on airway responsiveness to inhaled histamine. The patients were adults with mild to moderate asthma. Airway resistance (Raw) and intrathoracic gas volume (ITGV) were measured immediately before and 2, 3 and 21 days after vaccine or saline injection. Raw and ITGV values were used to calculate specific airway conductance (SGaw). Bronchial reactivity was expressed as the provocative dose of histamine diphosphate producing a decrease of 40% in SGaw (PD40). Fourteen (87%) of 16 asthmatics who received killed virus vaccine displayed a significant rise in serum antibody level as measured by single radial haemolysis in gel test. No significant alterations in mean Raw, ITGV and SGaw values were observed after viral vaccination. The median PD40 values for histamine also remained unchanged. However, an increased bronchial reactivity was observed in some patients after administration of virus vaccine or saline. Subclinical natural infection or allergen exposure cannot be excluded as possible causes of the increased airway reactivity in these patients. The side-effects of vaccination were minimal and no more harmful than those produced by saline injection. We conclude that the killed influenza virus vaccine used is effective in boosting serum antibody levels and is suitable for adult asthmatics when prophylactic immunisation is indicated.
对27名哮喘患者皮下注射多价灭活流感病毒疫苗或生理盐水,以研究流感疫苗对呼吸功能及气道对吸入组胺反应性的影响。这些患者为轻度至中度哮喘的成年人。在注射疫苗或生理盐水前以及注射后2天、3天和21天,测量气道阻力(Raw)和胸腔内气体容积(ITGV)。Raw和ITGV值用于计算比气道传导率(SGaw)。支气管反应性以使SGaw降低40%的磷酸组胺激发剂量(PD40)表示。16名接受灭活病毒疫苗的哮喘患者中,有14名(87%)通过凝胶单扩散溶血试验检测显示血清抗体水平显著升高。病毒疫苗接种后,未观察到Raw、ITGV和SGaw均值有显著变化。组胺的中位数PD40值也保持不变。然而,在接种病毒疫苗或生理盐水后,部分患者出现支气管反应性增加。不能排除亚临床自然感染或变应原暴露是这些患者气道反应性增加的可能原因。疫苗接种的副作用极小,并不比注射生理盐水产生的副作用更有害。我们得出结论,所用的灭活流感病毒疫苗在提高血清抗体水平方面有效,适用于有预防性免疫指征的成年哮喘患者。